Roblitinib

N/A

Report date: 2024/07/09 16:32:46
NME

Base Information

Drug NameRoblitinib
Drug Alias NameFGF-401NVP-FGF401
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 4 antagonists
TargetsFibroblast growth factor receptor 4
Therapy Area/IndicationsSolid tumoursCarcinoma, HepatocellularNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeTaiwan +[11] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEverest Medicines (Suzhou) IncNovartis Pharma AgBeijing Novartis Pharma Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, HepatocellularNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A